| P/E (FY) | 6.9 | Sales (TTM) | $255.6M |
| Earnings (TTM) | $37.1M | ROE | 22.26% |
| Net Margin | 6.88% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 1204.00% |
| Market Cap | $116.1M | Trading Days | 2123 |
| 52W High | 0.84 |
| 52W Low | 0.31 |
| % Off High | −42.86% |
| YTD | 37.14% | 1Y | 17.07% |
| 3Y | −39.05% | 5Y | −94.15% |
| Since incept. (ann.) | −29.10% |
Government Contract 95% · License 4% · Collaboration Revenue 1% · Non Cash Royalty Revenue 1%
| Ann. Volatility (1Y) | 90.47% | Ann. Volatility (3Y) | 96.41% |
| Sharpe (1Y) | 0.62 | Sharpe (3Y) | 0.31 |
| Max Drawdown (1Y) | −43.74% | Max Drawdown (3Y) | −78.72% |
| Beta (3Y, vs SPY) | 1.54 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ENGN | enGene Therapeutics Inc. | $117.9M | 0.8 |
| CRDL | Cardiol Therapeutics Inc. | $120.3M | — |
| OTLK | Outlook Therapeutics, Inc. | $109.3M | — |
| BDTX | Black Diamond Therapeutics, Inc. | $100.9M | 4.5 |
| TCRX | TScan Therapeutics, Inc. | $100.4M | — |
| PTHS | Pelthos Therapeutics Inc. | $96.5M | — |
| HUMA | Humacyte, Inc. | $140.0M | — |
| PROK | PROKIDNEY CORP. | $94.8M | — |
| CRBU | Caribou Biosciences, Inc. | $147.8M | — |
| CGTX | COGNITION THERAPEUTICS INC | $82.7M | — |
| TNYA | Tenaya Therapeutics, Inc. | $164.1M |
| — |
| ABOS | Acumen Pharmaceuticals, Inc. | $164.7M | — |
